TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Neurosense Therapeutics Ltd. ( (NRSN) ) has provided an update.
On July 10, 2025, NeuroSense Therapeutics Ltd. released a corporate video titled ‘End of Q2/2025 Update’ on their website. This update is part of their ongoing efforts to keep investors informed about the company’s progress and strategic direction, potentially impacting stakeholder confidence and market positioning.
The most recent analyst rating on (NRSN) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Neurosense Therapeutics Ltd. stock, see the NRSN Stock Forecast page.
Spark’s Take on NRSN Stock
According to Spark, TipRanks’ AI Analyst, NRSN is a Underperform.
Neurosense Therapeutics Ltd. faces substantial financial difficulties, including no revenue and negative equity, severely impacting its overall score. Technical indicators are neutral but do not offset financial weaknesses. The valuation is unattractive due to negative earnings and no dividend yield.
To see Spark’s full report on NRSN stock, click here.
More about Neurosense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. operates in the biotechnology industry, focusing on the development of treatments for neurodegenerative diseases. The company is based in Herzliya, Israel.
Average Trading Volume: 285,407
Technical Sentiment Signal: Buy
Current Market Cap: $50.38M
See more data about NRSN stock on TipRanks’ Stock Analysis page.